ReviewOxidative medicine and cellular longevity2026
Oxidative Stress in Neonatal Disease: Established Organ Injury and Emerging Evidence for Skeletal Involvement.
Review in Oxidative medicine and cellular longevity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Oxidative Stress in Neonatal Disease: Established Organ Injury and Emerging Evidence for Skeletal Involvement.Oxidative medicine and cellular longevity · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Reactive oxygen and nitrogen species participate in physiological signaling and adaptation during fetal and neonatal development, whereas excessive, prolonged, or spatially dysregulated production may contribute to oxidative and nitrosative tissue injury. Redox dysregulation has been extensively investigated in neonatal conditions, including bronchopulmonary dysplasia (BPD), hypoxic-ischemic encephalopathy, retinopathy of prematurity (ROP), necrotizing enterocolitis (NEC), congenital heart disease (CHD), and hyperbilirubinemia. Its relationship with bone metabolism is well established in adult and pediatric disorders, including osteoporosis, inflammatory bone loss, and iron-overload-related bone disease. However, the potential contribution of perinatal redox imbalance to early skeletal development remains comparatively underexplored. This narrative review critically examines the biochemical mechanisms of reactive species generation, their interaction with inflammatory pathways, and the experimental and clinical evidence linking redox dysregulation to neonatal organ injury. Particular attention is given to the developing skeleton as a potentially underrecognized target. Experimental studies indicate that excessive reactive species can impair chondrogenesis, alter osteoblast and osteoclast activity, disrupt collagen and osteogenic signaling, and interfere with skeletal growth. Human evidence is predominantly observational. Preliminary longitudinal data show inverse associations between cord-blood markers of oxidative DNA and protein modification and REMS-derived skeletal Z-scores during the first year of life. These findings suggest that early redox imbalance may impair bone quality and growth trajectories in newborns. Prospective studies integrating standardized redox biomarkers, bone-metabolism indices, imaging, nutrition, medication exposure, growth, and fracture outcomes are needed to determine whether redox dysregulation independently contributes to impaired skeletal development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.